Introduction {#s1}
============

Colorectal cancer (CRC) remains the most common gastrointestinal cancer in the United States, despite recent improvements in the diagnosis and treatment of the disease. The incidence and mortality rates of CRC for African Americans (AAs) are higher than in the U.S. general population [@pone.0030168-Alexander1], [@pone.0030168-Jemal1]. Many epidemiologic and genetic investigations have focused on AAs [@pone.0030168-Devaraj1], [@pone.0030168-Kupfer1], [@pone.0030168-Ollberding1], [@pone.0030168-Vinikoor1] with the goal of deciphering the reasons for such disparities. Whereas one cannot discount the contribution of socioeconomic factors, such as a more advanced stage of disease at diagnosis in AAs, other biological factors also contribute to the progression of colon cancer [@pone.0030168-Kupfer1]; [@pone.0030168-Williams1]. However, a biological basis for the existence of a more aggressive CRC in African American patients remains to be further elucidated. Genomic instability is a crucial feature in tumor development and there are at least 3 distinct pathways in CRC pathogenesis: chromosomal instability (CIN), microsatellite instability (MSI), and CpG island methylator phenotype pathways (CIMP) [@pone.0030168-Eaton1], [@pone.0030168-Pino1]. Any or all of these pathways may contribute to a more aggressive CRC biology in African Americans. Recent genome-wide association studies in CRC have shown not only strong evidence for common single nucleotide polymorphism (SNP) association in a number of genes and chromosomal regions, but also genetic heterogeneity in CRC association in AAs versus EAs [@pone.0030168-Kupfer1], [@pone.0030168-Jones1], [@pone.0030168-Katkoori1], [@pone.0030168-Kupfer2], [@pone.0030168-Roff1]. Different incidence of MSI and different level of methylation for functionally very relevant genes were also reported as a possible factors in CRC racial disparities [@pone.0030168-Eaton1], [@pone.0030168-Ashktorab1], [@pone.0030168-Brim1].

We hypothesized that the gene expression profiles of CRC in African-American and European-American patients may reveal biological differences between the two populations that could explain the more aggressive cancer phenotype in African-Americans. Thus, we performed genome-wide gene expression profiling in a large set of tumor samples that were matched for selected clinical variables. We analyzed our results on gene and pathway levels to identify key differences in tumor biology between African-American and European-American patients.

Methods {#s2}
=======

Patients {#s2a}
--------

One hundred and fourteen tumors (86 included in original analysis and 28 for validation study) and 40 normal tissues from de-identified CRC patients were obtained from the Institutional Research Board (IRB) approved University of North Carolina (UNC) Tissue Procurement Facility after UNC School of Medicine IRB approval for this study. Written informed consent was obtained from all patients. All samples were collected between 1999 and 2008 at the time of operation and snap frozen in liquid nitrogen. Patients with known familial adenomatous polyposis and hereditary non-polyposis CRC were excluded. De-identified data including race, tumor, node and metastasis (TNM), grade or differentiation, margin status, and survival were available for the majority of patients.

RNA Isolation and Microarray Hybridization {#s2b}
------------------------------------------

All RNA isolation and hybridization was performed on Agilent (Agilent Technologies, Santa Clara, CA) human whole genome 4X44 K DNA microarrays at UNC. RNA was extracted from macrodissected snap-frozen tumor samples using All prep Kits (Qiagen, Valencia, CA) and quantified using Nanodrop spectrophotometry (ThermoScientific, Wilmington, DE). RNA quality was assessed with the use of the Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). RNA was selected for hybridization using RNA integrity number and by inspection of the 18S and 28S ribosomal RNA. Similar RNA quality was selected across samples. One microgram of RNA was used as a template for cDNA preparation prior to hybridization to Agilent 4X44 K whole human genome arrays. cDNA was labeled with Cy5-dUTP and a reference control (Stratagene; Catalog Number \# 740000; Agilent Technologies, Santa Clara, CA; [@pone.0030168-Dybkaer1] was labeled with Cy3-dUTP using the Agilent low RNA input linear amplification kit and hybridized overnight at 65°C to Agilent 4X44 K whole human genome arrays. Arrays were washed and scanned using an Agilent scanner (Agilent Technologies, Santa Clara, CA).

All microarray data are in MIAME compliant form and raw and processed data has been deposited in the Gene Expression Omnibus (GEO); see <http://www.ncbi.nlm.nih.gov/geo/>, accession number: GSE28000.

Microarray and statistical analysis {#s2c}
-----------------------------------

All array data were normalized using LOWESS normalization. Data were excluded for genes with poor spot quality or genes that did not have a mean intensity greater than 10 for one of the two channels (green and red) in at least 70% of the experiments. The log2 ratio of the mean red intensity over mean green intensity was calculated for each gene followed by LOWESS normalization [@pone.0030168-Yang1]. Missing data were imputed using the k-nearest neighbors imputation (KNN) with k = 10 [@pone.0030168-Troyanskaya1]. Genes that were significantly up- or down-regulated were identified using Significance Analysis of Microarrays (SAM) [@pone.0030168-Tusher1]. SAM assigns a score to each gene on the basis of a change in gene expression relative to the standard deviation of repeated measurements. For genes with scores greater than an adjustable threshold, SAM uses permutations of the repeated measurements to estimate the percentage of genes identified by chance -- the false discovery rate (FDR). Analysis parameters (Delta) were set to result in FDR≤5%.

Network and gene ontology analysis {#s2d}
----------------------------------

Differentially expressed genes were investigated for network and gene functional interrelation by Ingenuity Pathways Analysis (IPA) software (Ingenuity Systems, [www.ingenuity.com](http://www.ingenuity.com); [@pone.0030168-Mori1]. IPA scans the set of input genes to identify networks by using Ingenuity Pathways Knowledge Base for interactions between identified 'Focus Genes', in this study, the differentially expressed genes between AA and EA and known and hypothetical interacting genes stored in the knowledge base in IPA software was used to generate a set of networks with a maximum network size of 35 genes/proteins. Networks are displayed graphically as genes/gene products ('nodes') and the biological relationships between the nodes ('edges'). All edges are from canonical information stored in the Ingenuity Pathways Knowledge Base. In addition, IPA computes a score for each network according to the fit of the user\'s set of significant genes. The score indicates the likelihood of the Focus Genes in a network from Ingenuity\'s knowledge base being found together due to random chance. A score of 3, as the cutoff for identifying gene networks, indicates that there is only a 1/1000 chance that the focus genes shown in a network are due to random chance. Therefore, a score of 3 or higher indicates a 99.9% confidence level to exclude random chance.

Ten-fold Cross Validation (Ten-f-CV) {#s2e}
------------------------------------

Ten-f-CV analysis [@pone.0030168-Camp1] was used to select smaller representative set of genes for validation study by qRT-PCR. Using Ten-f-CV analysis we identified 10 genes that can predict the ethnicity of the patient for whom the array was done with an error rate of 6%, suggesting that these 10 genes are representative of the entire gene list.

Quantitative real-time PCR {#s2f}
--------------------------

Validation of microarray results was performed on 28 CRC patients (10 AA, and 18 EA). Ten differentially expressed genes (identified by SAM and selected using the Ten-f-CV method) were validated by qRT-PCR. The hydroxymethylbilane synthase (HMBS) gene served as the housekeeping gene [@pone.0030168-Vandesompele1]. qRT-PCR was performed in duplicates using SYBR Green Gene Expression Assays (Applied Biosystems, Forester City, CA), which include pre-optimized primer sets specific for the genes being validated [@pone.0030168-Round1]. The validated genes were: Crystalline, beta B2 (CRYBB2), phosphoserine phosphatase homologue (PSPH), Adenosine deaminase-like (ADAL), V-set and immunoglobulin domain containing 10 like (VSIG10L), Chromosome 17 open reading frame 81 (C17orf81), Ankyrin repeat domain 36B (ANKRD36B). Zinc finger protein 83 (ZNF83), Rho GTPase activating protein 6 (ARHGAP6), WD repeat domain 8 (WDR8), TRNA nucleotidyl transferase, CCA-adding, 1 (TRNT1), and HMBS. Data were collected using the ABI PRISM 7500 sequence detection system (Applied Biosystems, Forster City, CA). qRT-PCR data for each sample were normalized using expression of the housekeeping gene HMBS. Graphs were prepared from normalized data relative to HMBS. Statistical analysis of these data was performed with a two-sided *t*-test or with a two-sided Wilcoxon rank-sum test if the expression data did not follow normal distribution.

Results {#s3}
=======

Identification of differentially expressed genes between AA and EA CRC patients {#s3a}
-------------------------------------------------------------------------------

Patient population characteristics for 43 AA and 43 EA patients were matched by TNM staging ([**Table 1**](#pone-0030168-t001){ref-type="table"}). The two populations were similar in age, gender and tumor localization. Forty non-tumor colon tissues (13 AAs and 27 EAs) were used for genetic comparisons of normal colon gene expression between AAs and EAs.

10.1371/journal.pone.0030168.t001

###### Clinical characteristics of the study population.

![](pone.0030168.t001){#pone-0030168-t001-1}

  *Characteristics*    *[Whites (n = 43)]{.ul}*   *[Blacks (n = 43)]{.ul}*   *[p-Value]{.ul}* [\*](#nt101){ref-type="table-fn"}          
  ------------------- -------------------------- -------------------------- ---------------------------------------------------- ------- -----------------------------------------
  Mean Age (y)                    67                        n/a                                     62.7                           n/a    0.18[\*\*](#nt102){ref-type="table-fn"}
  Gender                                                                                                                                 
  Male                            19                       44.19                                     25                           58.14  
  Female                          24                       55.81                                     18                           41.86                    0.28
  Location                                                                                                                               
  Right                           17                       39.53                                     22                           51.16  
  Left                            21                       48.83                                     21                           48.83  
  Unknown                         5                        11.62                                     0                            0.00                     0.06
  Tumor Stage                                                                                                                            
  1                               4                         9.30                                     4                            9.30   
  2                               16                       37.21                                     16                           37.21  
  3                               8                        18.60                                     8                            18.60  
  4                               15                       34.88                                     15                           34.88                    1.00

\*p-values based on Fisher\'s exact test.

\*\**p*-value based on t-test.

The comparison of gene expression profiles from AA and EA tumors using SAM revealed 95 gene transcripts to be differentially expressed between the two groups at FDRs of ≤5%. Fifty-eight genes were up regulated ([**Table 2**](#pone-0030168-t002){ref-type="table"}) and 37 down regulated ([**Table 3**](#pone-0030168-t003){ref-type="table"}) in tumor of AAs. We used Ingenuity Pathway Analysis to assess disease and pathway associations of these 95 genes that were differentially expressed in CRC tumors by race. The disease association analysis revealed associations of differentially expressed genes with genetic pathways that are linked to inflammatory response, hepatic system disease, developmental disorders, genetic disorders and neurologic disease (**[Table S1](#pone.0030168.s001){ref-type="supplementary-material"}**). The six top associated pathways for differentially expressed genes are shown in [**Fig. 1**](#pone-0030168-g001){ref-type="fig"}. Three of these six pathways are related to inflammatory and immune response. Differentially expressed genes in the five highest scoring networks are shown in [**Table 4**](#pone-0030168-t004){ref-type="table"}. Top associated network functions for differently expressed genes were: 1) organismal injury and abnormalities, gene expression, cellular development 2) lipid metabolism, small molecule biochemistry, molecular transport 3) cellular assembly and organization, organ development, carbohydrate metabolism 4) antigen presentation and inflammatory response, cellular movement 5) behavior, digestive system development and function, endocrine system development and function. One of these networks (network 4; antigen presentation and inflammatory response) is graphically represented in [**Fig. 2**](#pone-0030168-g002){ref-type="fig"}. Seven of the nine genes in this network were up regulated in AA patients (HLA-DQB1, IL33, PAK2, PROKR1, SAA2, TLR4, ZNF234), and two genes were down regulated (DHX58, IL27).

![Ingenuity analysis of top pathways affected in differentially expressed genes between African Americans and European Americans.\
Y-axis is an inverse indication of p-value or significance. The Threshold line marks the p = 0.05. (Note that 3 of 6 top pathways shown are related to inflammation and immune response).](pone.0030168.g001){#pone-0030168-g001}

![Gene network involved in "Inflammatory Response" generated by IPA for differentially expressed genes between African Americans and European Americans.\
Red symbols are assigned for up-regulated and green for down-regulated genes. Node shape corresponds to the functional role of molecules as shown in the legend. Direct or indirect interactions are shown by complete or dashed lines.](pone.0030168.g002){#pone-0030168-g002}

10.1371/journal.pone.0030168.t002

###### Up-regulated genes in colorectal tumors of African American patients.

![](pone.0030168.t002){#pone-0030168-t002-2}

  No.     Gene ID     Gene Name                                         Gene Title                                         Chromosome Location     Fold Change
  ----- ----------- -------------- ------------------------------------------------------------------------------------ ------------------------- -------------
  1        1415         CRYBB2                             Crystallin,beta B2 Crystallin,betaB2                          22q11.2-q12.1\|22q11.23      3.10
  2        5723          PSPH                                    Phosphoserinephosphatase                                     7p15.2-p15.1            3.38
  3       116285        ACSM1                        Acyl-CoAsynthetase medium-chain family member 1                             16p12.3              2.47
  4        23008       KLHDC10                                  Kelchdomain containing 10                                        7q32.2               1.48
  5        90865         IL33                                         Interleukin33                                              9p24.1               3.08
  6        6231         RPS26                                      Ribosomalprotein S26                                           12q13               1.63
  7       401081       FLJ22763                           Hypotheticalgene supported by AK026416                                 3q13.13              4.69
  8        10780        ZNF234                                    Zincfinger protein 234                                        19q13.31              2.09
  9        2863         GPR39                                  Gprotein-coupled receptor 39                                     2q21-q22              1.58
  10       60439        TTTY2                   Testis-specifictranscript, Y-linked 2 (non-protein coding)                       Yp11.2               1.55
  11       27012        KCNV1                            Potassiumchannel, subfamily V, member 1                              8q22.3-q24.1            2.58
  12       55020        TTC38                               Tetratricopeptiderepeat domain 38                                     22q13               1.67
  13      256380        SCML4                             Sexcomb on midleg-like 4 (Drosophila)                                   6q21                2.90
  14       5062          PAK2                           P21protein (Cdc42/Rac)-activated kinase 2                                 3q29                1.43
  15        540         ATP7B                           ATPase,Cu++ transporting, beta polypeptide                               13q14.3              1.66
  16       23562        CLDN14                                          Claudin14                                                21q22.3              2.35
  17       10911         UTS2                                           Urotensin2                                                1p36                2.45
  18       1416        CRYBB2P1                              Crystallin,beta B2 pseudogene 1                                  22q11.2-q12.1           1.59
  19       55282        LRRC36                               Leucinerich repeat containing 36                                    16q22.1              2.45
  20      348013        FAM70B                         Familywith sequence similarity 70, member B                                13q34               1.48
  21       81839        VANGL1                              Vang-like1 (van gogh, Drosophila)                                  1p11-p13.1             1.49
  22     100190939   LOC100190939                                HypotheticalLOC100190939                                       13q14.13              1.60
  23       4552          MTRR                5-methyltetrahydrofolate-homocysteinemethyltransferase reductase                 5p15.3-p15.2            1.74
  24      348751      LOC348751                               Hypotheticalprotein LOC348751                                      2q33.1               1.78
  25       7099          TLR4                                      Toll-likereceptor 4                                          9q32-q33              1.95
  26       5789         PTPRD                         Proteintyrosine phosphatase, receptor type, D                            9p23-p24.3             2.17
  27       3043          HBB                                         Hemoglobin,beta                                             11p15.5              1.82
  28      146456        TMED6                    Transmembraneemp24 protein transport domain containing 6                        16q22.1              2.61
  29      253039      LOC253039                                   HypotheticalLOC253039                                          9q33.2               1.32
  30       2037        EPB41L2                         Erythrocytemembrane protein band 4.1-like 2                                6q23                1.81
  31       59352         LGR6                   Leucine-richrepeat-containing G protein-coupled receptor 6                       1q32.1               2.28
  32       2689          GH2                                         Growthhormone 2                                             17q24.2              1.42
  33       4886         NPY1R                                   NeuropeptideY receptor Y1                                      4q31.3-q32             4.03
  34      283345       RPL13P5                              Ribosomalprotein L13 pseudogene 5                                   12p13.31              1.99
  35       3119        HLA-DQB1                    Majorhistocompatibility complex, class II, DQ beta 1                          6p21.3               1.55
  36      140881       DEFB129                                      Defensin,beta 129                                             20p13               1.44
  37      144568        A2ML1                                  Alpha-2-macroglobulin-like1                                      12p13.31              1.59
  38       10783         NEK6                         NIMA(never in mitosis gene a)-related kinase 6                          9q33.3-q34.11           1.53
  39      130399        ACVR1C                                  ActivinA receptor, type IC                                       2q24.1               2.32
  40       27283        TINAG                              Tubulointerstitialnephritis antigen                                 6p11.2-p12             1.97
  41      116511        MAS1L                                       MAS1oncogene-like                                             6p21                1.47
  42       8908          GYG2                                          Glycogenin2                                               Xp22.3               1.73
  43      145447       ABHD12B                               Abhydrolasedomain containing 12B                                    14q22.1              3.20
  44      401577      LOC401577                               Hypotheticalprotein LOC401577                                      Xp22.33              1.49
  45       10887        PROKR1                                    Prokineticinreceptor 1                                         2p13.1               1.44
  46       4889         NPY5R                                   NeuropeptideY receptor Y5                                       4q31-q32              1.50
  47      327657       SERPINA9     Serpinpeptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 9                                1.37
  48       4860           NP                                     Nucleosidephosphorylase                                         14q13.1              1.47
  49       1056          CEL                        Carboxylester lipase (bile salt-stimulated lipase)                           9q34.3               1.49
  50       81796       SLCO5A1                  Solutecarrier organic anion transporter family, member 5A1                       8q13.3               1.34
  51       6289          SAA2                                        Serumamyloid A2                                           11p15.1-p14            2.29
  52      171558        PTCRA                                PreT-cell antigen receptor alpha                                    6p21.3               1.31
  53       8309         ACOX2                            Acyl-CoenzymeA oxidase 2, branched chain                                3p14.3               2.21
  54       79857       FLJ13224                                Hypotheticalprotein FLJ13224                                     12p11.21              1.28
  55       9376        SLC22A8                Solutecarrier family 22 (organic anion transporter), member 8                                           1.33
  56       7712         ZNF157                                    Zincfinger protein 157                                         Xp11.2               1.40
  57        10           NAT2                      N-acetyltransferase2 (arylamine N-acetyltransferase)                           8p22                2.45
  58      283422       C12orf36                             Chromosome12 open reading frame 36                                   12p13.1              2.07

10.1371/journal.pone.0030168.t003

###### Down-regulated genes in colorectal tumors of African American patients.
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  No.     Gene ID     Gene Name                                        Gene Title                                      Chromosome Location   Fold Change
  ----- ----------- -------------- ---------------------------------------------------------------------------------- --------------------- -------------
  1        57730       ANKRD36B                                 Ankyrin repeatdomain 36B                                     2q11.2             0.48
  2        23587       C17orf81                            Chromosome 17open reading frame 81                                17p13.1            0.44
  3         415          ARSE                         Arylsulfatase E(chondrodysplasia punctata 1)                           Xp22.3             0.21
  4         395        ARHGAP6                               Rho GTPaseactivating protein 6                                  Xp22.3             0.58
  5       146547        PRSS36                                    Protease, serine,36                                        16p11.2            0.36
  6       161823         ADAL                                   Adenosine deaminase-like                                     15q15.3            0.65
  7       246778         IL27                                        Interleukin 27                                            ---              0.36
  8       644246      LOC644246                              Hypothetical proteinLOC644246                                  17q21.31            0.42
  9        79132        DHX58                            DEXH (Asp-Glu-X-His)box polypeptide 58                              17q21.2            0.54
  10       51095        TRNT1                          TRNA nucleotidyltransferase, CCA-adding, 1                            3p25.1             0.60
  11       55769        ZNF83                                    Zinc fingerprotein 83                                       19q13.3            0.65
  12       64093        SMOC1                            SPARC relatedmodular calcium binding 1                              14q24.2            0.44
  13      642946         LQK1                                    Hypothetical LOC642946                                      1q32.3             0.47
  14      147645       VSIG10L                     V-set andimmunoglobulin domain containing 10 like                        19q13.41            0.65
  15       26150        RIBC2                               RIB43A domainwith coiled-coils 2                                22q13.31            0.48
  16       57531        HACE1            HECT domainand ankyrin repeat containing, E3 ubiquitin protein ligase                                  0.60
  17       5303          PIN4          Protein (peptidylprolylcis/trans isomerase) NIMA-interacting, 4 (parvulin)             Xq13              0.62
  18       8820         HESX1                                        HESX homeobox1                                          3p14.3             0.56
  19       79609      C14orf138                           Chromosome 14open reading frame 138                                14q21.3            0.62
  20        816         CAMK2B                     Calcium/calmodulin-dependent proteinkinase II beta                  22q12\|7p14.3-p14.1      0.64
  21       1953         MEGF6                                  Multiple EGF-like-domains6                                    1p36.3             0.55
  22       79682        MLF1IP                                  MLF1 interactingprotein                                      4q35.1             0.51
  23       51340        CRNKL1                  Crooked neckpre-mRNA splicing factor-like 1 (Drosophila)                     20p11.2            0.61
  24     100287616   LOC100287616                           Hypothetical proteinLOC100287616                                 15q24.1            0.54
  25      201973       CCDC111                              Coiled-coil domaincontaining 111                                 4q35.1             0.67
  26       3712          IVD                               Isovaleryl CoenzymeA dehydrogenase                               15q14-q15           0.62
  27       4942          OAT                           Ornithine aminotransferase(gyrate atrophy)                             10q26             0.60
  28       57830       KRTAP5-8                             Keratin associatedprotein 40306                                  11q13.4            0.50
  29      388610        TRNP1                               TMF1-regulated nuclearprotein 1                                  1p36.11            0.47
  30       26152        ZNF337                                   Zinc fingerprotein 337                                      20p11.1            0.62
  31     100287572   LOC100287572                                 Similar tohCG1996962                                        18q23             0.63
  32       1427         CRYGS                                      Crystallin, gammaS                                       3q25-qter           0.65
  33       4435         CITED1      Cbp/p300-interacting transactivator,with Glu/Asp-rich carboxy-terminal domain, 1         Xq13.1             0.55
  34      339318        ZNF181                                   Zinc fingerprotein 181                                     19q13.11            0.69
  35       49856         WDR8                                      WD repeatdomain 8                                         1p36.3             0.71
  36      221322       C6orf170                            Chromosome 6open reading frame 170                                6q22.31            0.70
  37      284018       C17orf58                            Chromosome 17open reading frame 58                                17q24.2            0.62

10.1371/journal.pone.0030168.t004

###### Functional association of differentially expressed genes generated by IPA.
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  *ID*                                                    *Focus Molecules in Network*                                                   *Score*   *Focus Molecules*                                          *Top Functions*
  ------ ------------------------------------------------------------------------------------------------------------------------------ --------- ------------------- ------------------------------------------------------------------------------------------------
  1       ARSE, C6ORF170, CITED1, CRYBB2, CRYGS, EPB41L2, HBB (includes EG:3043), HESX1, HLA-DQB1, IVD, NAT2, OAT, PTPRD, RPS26, ZNF83   **28**         **15**                   Organismal Injury and Abnormalities, Gene Expression, Cellular Development
  2           ACVR1C, ATP7B, C17ORF81, GH2, GPR39, MLF1IP, NP, PIN4, PTCRA, SLC22A8, TRNT1, TTC38, VANGL1,WDR8 (includes EG:49856)       **26**         **14**                       Lipid Metabolism, Small Molecule Biochemistry, Molecular Transport
  3                              ANKRD36B, CRNKL1, GYG2, KCNV1, KLHDC10, MEGF6, MTRR, NEK6, PSPH, RIBC2, ZNF337                          **20**         **11**                 Cellular Assembly and Organization, Organ Development, Carbohydrate Metabolism
  4                                      DHX58, HLA-DQB1, IL27, IL33, PAK2, PROKR1, SAA2, TLR4, ZNF234                                   **15**          **9**                         Antigen Presentation, Inflammatory Response, Cellular Movement
  5                                                  CAMK2B, CEL, NPY1R, NPY5R, SCML4, UTS2                                               **9**          **6**         Behavior, Digestive System Development and Function, Endocrine System Development and Function

We also performed SAM analysis using non-tumor colon tissues from AA and EA patients and did not see differential gene expression (data not shown), suggesting that the changes we identified are tumor microenvironment specific.

Validation of microarray results {#s3b}
--------------------------------

In order to select a representative group of genes for qRT-PCR validation of differentially expressed genes between AA and EA CRC patients, we performed a 10-fold cross validation analysis that resulted in the selection of following ten genes: CRYBB2, PSPH, ADAL, VSIG10L, C17orf81, ANKRD36B, ZNF835, ARHGAP6, TRNT1 and WDR8.

Expression of these ten genes was validated by qRT-PCR on an independent test set of 28 CRC patients (10 AA and 18 EA). The qRT-PCR results are shown in [**Fig. 3**](#pone-0030168-g003){ref-type="fig"}. Two of the 10 differentially expressed genes were up-regulated in AA vs. EA CRC patients; CRYBB2, p = 0.0004 and PHSP, p = 0.001 ([**Fig. 3**](#pone-0030168-g003){ref-type="fig"} **; Panel A.**). Eight were down-regulated in AA vs. EA CRC patients; VSIG10L, p = 0.015; C17orf81, p = 0.032; WDR8, p = 0.002; TRNT1, p = 0.004; ANKRD36B, p = 0.044; ARHGAP6, p = 0.049; ADAL, p = 0.074; ZNF83, p = 0.11; ([**Fig. 3**](#pone-0030168-g003){ref-type="fig"} **; Panel B.**). The direction of change (up or down regulation) for the qRT-PCR validated genes was in agreement with SAM results. Eight of ten genes in the qRT-PCR validation study reached a statistically significant level (p\<0.05; CRYBB2, PSPH, C17orf81, ANKRD36B, VSIG10L, WDR8, TRNT1 and ARHGAP6).

![qRT-PCR validation analysis of expression of ten selected genes between African American and European American CRC patients.\
Panel A. Expression of two up-regulated genes in African American colorectal cancer patients: CRYBB2, PSPH. Panel B. Expression of eight down-regulated genes in African American colorectal cancer patients: ARHGAP6, VSIG10L, C17orf81, ZNF83, ANKRD36B, ADAL, WDE8 and TNRT1. Points are relative Ct values for the individual samples; horizontal lines are mean values for the sample set. The significantly differentially expressed genes (p\<0.05) between African-American (n = 10) vs. European-American (n = 18) CRC tumors are labeled by a star. Graphs were prepared from normalized genes expression data relative to the housekeeping (HMBS) gene.](pone.0030168.g003){#pone-0030168-g003}

Discussion {#s4}
==========

The causes of the CRC disparity that exists between AA and EA patients remain to be fully elucidated. Although most of the research on this disparity has focused on socioeconomic factors, recent findings strongly support the role of genetic and biological factors. Genetic differences between AA and EA CRC patients were reported for SNP association, for incidence of MSI and level of gene methylation [@pone.0030168-Kupfer1], [@pone.0030168-Ashktorab1], [@pone.0030168-Brim1]. Any of these differences can result in differential gene expression between AA and EA CRC patients. In this study we analyzed the gene expression profiles of 86 tumors from 43 AA and 43 EA patients. Significant differences in the expression of genes related to immune response and inflammation within the tumor micro-environment were identified between these two groups. This interpretation was supported by both disease association and pathway analyses. Most of the immune-related genes had higher expression in tumors from African-American patients than in those from European-American patients. Although preliminary, these findings are novel and could have implications for cancer therapy. From the present study, we do not know why CRC from African-American patients would have a different immunologic profile than tumors from European-American patients. We hypothesize that the causes of these differences are multifactorial. Chronic inflammation is thought to be a causative factor in colorectal carcinogenesis [@pone.0030168-Secher1], [@pone.0030168-Westbrook1]. It was shown that an immune response signature in the liver of cancer patients predicts metastasis and recurrence of hepato-cellular carcinoma [@pone.0030168-deVisser1]. Thus, future studies should evaluate whether the immunologic profile of CRC in African-American patients is a predisposing factor for tumor progression and metastasis. Previous investigations identified a two-gene tumor signature (CRYBB2 and PSPHL) that accurately differentiated between African-American and European-American prostate cancer patients [@pone.0030168-Wallace1]. Those two genes were also differentially expressed between African-American and European American breast cancer patients [@pone.0030168-Martin1] In this study we found up-regulation of CRYBB2 and PSPH gene in CRC of African-American patients. Mutations in the CRYBB2 gene are also responsible for familial cataract [@pone.0030168-Litt1]. PSPHL is a homolog of PSPH. Interestingly, PSPH is located on chromosome 7p15.2, a chromosomal region known to have gain of function related to advanced tumor stage in non-small-cell lung adenocarcinoma [@pone.0030168-Choi1]. It was shown that increased expression of PSPH in non-small-cell lung cancer corresponds to clinical response to treatment with erlotinib [@pone.0030168-Tan1]. Thus, it is possible that higher expression of PSPH contributes to CRC susceptibility in AAs and that the levels of PSPH expression may be correlated with response to anti-EGFR treatment. These possibilities will have to be tested in future studies. Considering down-regulated genes in AAs we found lower expression of the C17orf81 gene. Down regulation of this gene was associated with colon cancer [@pone.0030168-Saaf1], suggesting that lower expression of this gene can contribute to more aggressive CRC in AAs. Other down regulated genes in AAs include: TRNT1 (involve in RNA processing; [@pone.0030168-Nagaike1]); ARHGAP6 (promotes actin remodeling: [@pone.0030168-Prakash1]); WDR8 (facilitates formation of multiprotein complexes: [@pone.0030168-Ewing1]). Considering the cellular functions of these genes it is not hard to envision how their expression may influence aggressiveness of CRC.

Whole-genome gene expression analysis experiments can be prone to findings that are either unique to a selected patient population or are artificially created by the applied technology. To exclude the possibility of an artifact, two different approaches were used to cross validate our gene expression data. First, we compared our results of the differentially expressed genes between 86 tumors and 40 surrounding non-tumor tissues with those from a published meta-analysis of five CRC gene expression datasets in Oncomine [@pone.0030168-Alon1], [@pone.0030168-Kaiser1], [@pone.0030168-Ki1], [@pone.0030168-Kurashina1], [@pone.0030168-Notterman1]; **[Table S2](#pone.0030168.s002){ref-type="supplementary-material"}**. We found a very good agreement between our results and the results of the other 5 meta-analyses. Of the top 20 over-expressed genes in CRC tumors across the 5 other meta-analyses (Oncomine; <https://www.oncomine.org>), 15 were also found to be significantly up-regulated (FDR, \<5%) in our study. Of the top 20 under-expressed genes in CRC tumors across the 5 other meta-analyses, 17 were significantly down-regulated (FDR, \<5%) in our study.

Second, we validated the expression of ten key genes via qRT-PCR and confirmed differences in gene expression between CRCs of AAs and EAs for eight of them.

In conclusion, the gene expression profile of CRC corresponds to differences in tumor biology between African-American and European-American patients. The implications of these differences in disease aggressiveness and response to therapy should be evaluated in future studies.
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